AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30136704 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT) in addition to conventional therapy
Number of subjects: 92
Study 30136704 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 92
Study 30136704 — intervention group
Group type: EXPERIMENTAL
Intervention: CRRT
Number of subjects: 92
Study 26968939 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-randomised trial
Number of subjects: 128
Study 25623903 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg daily)
Number of subjects: 137
Study 25623903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 23042974 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB) + Mycophenolate mofetil (MMF)
Number of subjects: 126
Study 23042974 — intervention group
Group type: COMPARATOR
Intervention: Daclizumab (DZB) - Mycophenolate mofetil (MMF)
Number of subjects: 126
Study 21107264 — intervention group
Group type: EXPERIMENTAL
Intervention: Masimo 'Radical 7'
Number of subjects: 52
Study 21107264 — intervention group
Group type: COMPARATOR
Intervention: Nellcor 'N 600'
Number of subjects: 52
Study 21107264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 52
Study 18363314 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (mean daily dose of 36.7 +/- 11.2 mg over > or = 26 days)
Number of subjects: 34
Study 18363314 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 34
Study 16209971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian education (2 counseling sessions)
Number of subjects: 47
Study 16209971 — intervention group
Group type: COMPARATOR
Intervention: Usual care (self-help literature)
Number of subjects: 47
Study 12029450 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid infusion
Number of subjects: 131
Study 12029450 — intervention group
Group type: COMPARATOR
Intervention: Control (no colloid infusion)
Number of subjects: 131
Study 10999121 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO therapy (40 U/kg biweekly for 6 weeks)
Number of subjects: 40
Study 10999121 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving EPO)
Number of subjects: 40
Study 7575309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping motion challenges at initial symptoms
Number of subjects: 20
Study 7575309 — intervention group
Group type: COMPARATOR
Intervention: Stopping motion challenges at moderate nausea
Number of subjects: 20
Study 2328174 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diamorphine using a patient‐controlled analgesia system (PCAS)
Number of subjects: 30
Study 2328174 — intervention group
Group type: EXPERIMENTAL
Intervention: extradural diamorphine
Number of subjects: 30
Study 2328174 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. morphine
Number of subjects: 30
Study 2328174 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study 7261664 — intervention group
Group type: EXPERIMENTAL
Intervention: clobetasone butyrate 0.05%
Number of subjects: 29
Study 7261664 — intervention group
Group type: EXPERIMENTAL
Intervention: fluocortin butylester 0.75%
Number of subjects: 29
Study 7261664 — intervention group
Group type: COMPARATOR
Intervention: hydrocortisone acetate 1%
Number of subjects: 29
Study 7261664 — intervention group
Group type: COMPARATOR
Intervention: placebo creams
Number of subjects: 29
Study 30506558 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 20 μg
Number of subjects: 108
Study 30506558 — intervention group
Group type: COMPARATOR
Intervention: Carbetocin 100 μg
Number of subjects: 108
Study 28526920 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg once-weekly
Number of subjects: 75
Study 28526920 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 25940767 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 146
Study 25940767 — intervention group
Group type: COMPARATOR
Intervention: Telephone support condition (Control)
Number of subjects: 146
Study 23374910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotspot-targeted interventions including larviciding, focal screening and treatment, distribution of long-lasting insecticide-treated nets, and indoor residual spraying.
Number of subjects: 0
Study 23374910 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 21272393 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT (Think, Feel, Do)
Number of subjects: 20
Study 21272393 — intervention group
Group type: COMPARATOR
Intervention: Control condition (delayed cCBT)
Number of subjects: 20
Study 21272393 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from participants
Number of subjects: 20
Study 19320633 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of perceived stress, drinking severity, psychiatric comorbidity, self-efficacy, craving, and positive treatment outcome expectancies
Number of subjects: 0
Study 17353403 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (50 mg every other day)
Number of subjects: 22071
Study 17353403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 15096081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (titrated up to 50-150 mg/day)
Number of subjects: 225
Study 15096081 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (titrated up to 40-60 mg/day)
Number of subjects: 225
Study 15096081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 225
Study 15096081 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 225
Study 12106936 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 to 50 mg/day)
Number of subjects: 106
Study 12106936 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg)
Number of subjects: 106
Study 12106936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 9641366 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine 0.1 mg daily
Number of subjects: 50
Study 9641366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7943696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurare (0.125 mg.kg‐1 or 0.25 mg.kg‐1)
Number of subjects: 0
Study 7943696 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium (1 mg.kg‐1)
Number of subjects: 0
Study 7943696 — intervention group
Group type: COMPARATOR
Intervention: Tubocurare controls
Number of subjects: 0
Study 3287770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of pirenzepine (75 mg/day) and cimetidine (400 mg at bedtime)
Number of subjects: 60
Study 3287770 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine monotherapy (1000 mg/day)
Number of subjects: 60
Study 31888764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring during the first 72 hours of life
Number of subjects: 1600
Study 31888764 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (no cerebral oxygenation monitoring)
Number of subjects: 1600
Study 28886351 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 or 30 mg)
Number of subjects: 64
Study 28886351 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucocorticoid treatment)
Number of subjects: 64
Study 24699430 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based working memory training and exercises in word fluency and semantic structuring
Number of subjects: 36
Study 24699430 — intervention group
Group type: COMPARATOR
Intervention: Standard memory therapy provided in the rehabilitation center
Number of subjects: 36
Study 24113708 — intervention group
Group type: EXPERIMENTAL
Intervention: High-repetition, moderate-intensity resistance training (n = 12) for 12 weeks, performed twice a week for 75 minutes per session.
Number of subjects: 19
Study 24113708 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7), no intervention.
Number of subjects: 19
Study 24113708 — intervention group
Group type: COMPARATOR
Intervention: Comparison between exercise and control groups.
Number of subjects: 19
Study 24113708 — intervention group
Group type: COMPARATOR
Intervention: Both groups (exercise and control).
Number of subjects: 19
Study 22071714 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 28
Study 22071714 — intervention group
Group type: EXPERIMENTAL
Intervention: Desaturating COPD patients
Number of subjects: 28
Study 22071714 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients with high CRP
Number of subjects: 28
Study 19808135 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 300 mg/d
Number of subjects: 28
Study 19808135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16980242 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS065D (Xclair)
Number of subjects: 20
Study 16980242 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 20
Study 16807617 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan mesylate 600 mg once daily
Number of subjects: 198
Study 16807617 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan mesylate 600 mg once daily plus HBPM
Number of subjects: 198
Study 16807617 — intervention group
Group type: COMPARATOR
Intervention: Control group (eprosartan alone)
Number of subjects: 198
Study 10690446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (20 minutes of treadmill running at 70-80% of maximal heart rate)
Number of subjects: 15
Study 10690446 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic exercise (Wingate anaerobic test)
Number of subjects: 15
Study 10690446 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained women)
Number of subjects: 15
Study 9327314 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 122
Study 9327314 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 122
Study 8418225 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days
Number of subjects: 41
Study 8418225 — intervention group
Group type: COMPARATOR
Intervention: Loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days
Number of subjects: 41
Study 3671896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 11
Study 3671896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30516088 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group ($20 for top third scores)
Number of subjects: 81
Study 30516088 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard administration instructions)
Number of subjects: 81
Study 28854956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dose RTX (1×500 mg or 1×200 mg)
Number of subjects: 140
Study 28854956 — intervention group
Group type: COMPARATOR
Intervention: Standard low dose RTX (1×1000 mg)
Number of subjects: 140
Study 24299470 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 84
Study 24299470 — intervention group
Group type: COMPARATOR
Intervention: Clipping
Number of subjects: 84
Study 24261522 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based asthma program
Number of subjects: 1316
Study 20931328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (cholecystokinin type-2 receptor agonist)
Number of subjects: 0
Study 20931328 — intervention group
Group type: COMPARATOR
Intervention: Morphine (pre-conditioning)
Number of subjects: 0
Study 20931328 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (μ-opioid receptor antagonist)
Number of subjects: 0
Study 18814906 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting human insulin (1 unit/kg)
Number of subjects: 264
Study 18814906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 20929566 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria intervention (intermittent screening and treatment of malaria)
Number of subjects: 101
Study 20929566 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy intervention (training workshops and support for teachers)
Number of subjects: 101
Study 20929566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions combined (malaria and literacy)
Number of subjects: 101
Study 20929566 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither intervention implemented)
Number of subjects: 101
Study 16154017 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based combination drug regimen
Number of subjects: 19257
Study 16154017 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based combination drug regimen
Number of subjects: 19257
Study 16154017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate adjustment
Number of subjects: 19257
Study 12039619 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg buprenorphine per day
Number of subjects: 105
Study 12039619 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg buprenorphine per day
Number of subjects: 105
Study 12039619 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg buprenorphine per day
Number of subjects: 105
Study 9569110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG therapy (81 mg) in Group 1
Number of subjects: 80
Study 9569110 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG therapy (54 mg) in Group 2
Number of subjects: 80
Study 8306416 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin 20 mg/m2 only
Number of subjects: 97
Study 8306416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin 20 mg/m2 after pretreatment with WR-2721, 910 mg/m2
Number of subjects: 97
Study 3189495 — intervention group
Group type: EXPERIMENTAL
Intervention: Blu Blocker
Number of subjects: 22
Study 3189495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vuarnet 4006
Number of subjects: 22
Study 3189495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vuarnet 4006 (outdoors in shaded daylight)
Number of subjects: 22
Study 3189495 — intervention group
Group type: COMPARATOR
Intervention: 1.0 log unit neutral density filter (NDF)
Number of subjects: 22
Study 30649344 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding sows once daily at 1530 h
Number of subjects: 174
Study 30649344 — intervention group
Group type: COMPARATOR
Intervention: Control (Feeding sows once daily at 0730 h)
Number of subjects: 174
Study 30649344 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding sows daily at 1130 h
Number of subjects: 174
Study 29432331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus risperidone and biperiden
Number of subjects: 68
Study 29432331 — intervention group
Group type: COMPARATOR
Intervention: Risperidone and biperiden (Control)
Number of subjects: 68
Study 27545697 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (2 million international units every 8 hours)
Number of subjects: 166
Study 27545697 — intervention group
Group type: COMPARATOR
Intervention: Colistin plus rifampicin (not detailed in dosage or duration)
Number of subjects: 166
Study 24819327 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic tension-free vaginal tape (TVT)
Number of subjects: 569
Study 24819327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TVT-O)
Number of subjects: 569
Study 22395280 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive gear (CG)
Number of subjects: 18
Study 22395280 — intervention group
Group type: COMPARATOR
Intervention: No gear (NON)
Number of subjects: 18
Study 22395280 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 19145637 — intervention group
Group type: EXPERIMENTAL
Intervention: Daming capsule (DMC) 2 g b.i.d. for 6 weeks
Number of subjects: 60
Study 19145637 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg o.d. for 6 weeks
Number of subjects: 60
Study 17325925 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (320 mg Iota/ml) used in MDCTA
Number of subjects: 173
Study 15505151 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT) type A injections into the submandibular salivary glands
Number of subjects: 45
Study 15505151 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine treatment
Number of subjects: 45
Study 11266239 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate (HFA-BDP) 800 microg day(-1)
Number of subjects: 198
Study 11266239 — intervention group
Group type: COMPARATOR
Intervention: HFA-fluticasone propionate (HFA-FP) 1000 microg day(-1)
Number of subjects: 198
Study 9684804 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen deficiency
Number of subjects: 1192
Study 9684804 — intervention group
Group type: COMPARATOR
Intervention: Non-deficient group
Number of subjects: 1192
Study 7985248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWHs)
Number of subjects: 66
Study 7985248 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH), dextran, or vitamin K-antagonists
Number of subjects: 66
Study 2968595 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) for 12 weeks
Number of subjects: 24
Study 2968595 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) + cholestyramine
Number of subjects: 24
Study 2968595 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine alone for 12 weeks
Number of subjects: 24
Study 2968595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (with simvastatin 20 mg/day)
Number of subjects: 24
Study 29976233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpyloric enteral nutrition
Number of subjects: 141
Study 29976233 — intervention group
Group type: COMPARATOR
Intervention: Gastric enteral nutrition
Number of subjects: 141
Study 26340864 — intervention group
Group type: EXPERIMENTAL
Intervention: Baltimore Experience Corps program (community-based volunteer program) for 2 years
Number of subjects: 123
Study 26340864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study 24636808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri probiotic preparation
Number of subjects: 30
Study 24636808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23576138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Oxaliplatin (500 mg/m² Pemetrexed + 100 mg/m² Oxaliplatin)
Number of subjects: 45
Study 23576138 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed plus Cisplatin (500 mg/m² Pemetrexed + 75 mg/m² Cisplatin)
Number of subjects: 45
Study 20005617 — intervention group
Group type: EXPERIMENTAL
Intervention: Community breastfeeding support groups
Number of subjects: 7
Study 18775035 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced information regarding life-sustaining treatment alternatives
Number of subjects: 78
Study 18775035 — intervention group
Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 78
Study 16768770 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonectomy with heated intraperitoneal chemotherapy
Number of subjects: 22
Study 16768770 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cancer resection (CCR O)
Number of subjects: 22
Study 16768770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PCI score less than 13
Number of subjects: 22
Study 11805764 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (1.0 mg/kg)
Number of subjects: 100
Study 11805764 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.15 mg/kg)
Number of subjects: 100
Study 10563126 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sevoflurane in oxygen
Number of subjects: 50
Study 10563126 — intervention group
Group type: COMPARATOR
Intervention: 4.5% sevoflurane in 50% nitrous oxide
Number of subjects: 50
Study 7786375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory rotation (37 students)
Number of subjects: 106
Study 7786375 — intervention group
Group type: COMPARATOR
Intervention: Usual rotation on general medicine wards (69 students)
Number of subjects: 106
Study 2120178 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 300 mg twice daily for ten days
Number of subjects: 36
Study 2120178 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg twice daily for ten days
Number of subjects: 36
Study 2120178 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin
Number of subjects: 36
Study 356739 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride
Number of subjects: 30
Study 356739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31927581 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich diet (Prot)
Number of subjects: 163
Study 31927581 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated fat-rich diet (Unsat)
Number of subjects: 163
Study 31927581 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (Carb)
Number of subjects: 163
Study 28982261 — intervention group
Group type: EXPERIMENTAL
Intervention: Central IRB review
Number of subjects: 34
Study 28982261 — intervention group
Group type: COMPARATOR
Intervention: Local IRB review
Number of subjects: 34
Study 27486817 — intervention group
Group type: COMPARATOR
Intervention: Sm-153-EDTMP alone
Number of subjects: 44
Study 27486817 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sm-153-EDTMP and PSA-TRICOM vaccine
Number of subjects: 44
Study 25169910 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 88
Study 25169910 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 88
Study 22520644 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg daily for 3 days prior to the abortion
Number of subjects: 16
Study 22520644 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 16
Study 21866687 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Relactation)
Number of subjects: 40
Study 21866687 — intervention group
Group type: COMPARATOR
Intervention: Group B (Control: Exclusive breastfeeding)
Number of subjects: 40
Study 18819444 — intervention group
Group type: EXPERIMENTAL
Intervention: New high-cost antiepileptic drugs
Number of subjects: 0